Miocamycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Miocamycin
Accession Number
DB13287
Description

Miocamycin is a macrolide type antimicrobial 1. This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia 2. It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment 1.

Type
Biotech
Groups
Approved
Synonyms
  • Midecamycin acetate

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Miocamycin.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Miocamycin.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Miocamycin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Miocamycin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Miocamycin.
AlectinibThe metabolism of Alectinib can be decreased when combined with Miocamycin.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Miocamycin.
AlpelisibThe metabolism of Alpelisib can be decreased when combined with Miocamycin.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Miocamycin.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Miocamycin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
J01FA11 — Miocamycin
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
3T48CPS7U2
CAS number
55881-07-7

References

General References
  1. Holliday SM, Faulds D: Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1993 Oct;46(4):720-45. doi: 10.2165/00003495-199346040-00008. [PubMed:7506653]
  2. Kegg Japanese Pharmacopoeia [Link]
ChemSpider
16735908
RxNav
236200
ChEMBL
CHEMBL1091024
Wikipedia
Miocamycin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Granule, for suspensionOral250 MG/5ML
Granule, for suspensionOral300 MG
Granule, for suspensionOral600 MG
Granule, for suspensionOral900 MG
Tablet, coated300 MG
Tablet, coated600 MG
Tablet300 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [PubMed:11020135]

Drug created on June 23, 2017 14:39 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates